RAC

1.74%

$1.47 race oncology ltd

General Comments / Chat, page-11590

First 11590 Last

Share
Profile

Follow
australiasydney

683 Posts.

297

30/09/24

15:14

Post #: 75907963
Share
Originally posted by JBeez_: ↑

Note this refers to a 10% royalty paid to RAC for the out-licensing of bisantrene, which is not necessarily the same royalty paid to RAC holders.

I actually think 10% is a very conservative estimate, and as far as I can tell they make no mention of upfronts and milestones that will surely be incorporated into any transaction.

There are probably 5 super conservative estimates in that screen shot alone:

no upfronts or milestones
10% royalty
32% success rate (based on industry-accepted ranges that do not account for the clinical history of bisantrene)
target market that excludes the highest anthracycline market in the world (and every other jurisdiction outside the US and Europe)
10% peak market penetration

I find the 10% market penetration most peculiar. If you assume for a second that CPACs is demonstrated unequivocally in the clinical trials, you're telling me that 90% of the market are going to ignore a therapy that is proven to not only improve the rate of cancer-killing, but protects the patients from cardiotoxic harm. That is a ridiculous assumption, and is antithetical to the core principles of medicine in the first place. I personally think if you assume that bisantrene makes it to the market, your uptake rates have to be far higher, AT LEAST 50% but possibly far higher. I just cannot see a physician in the world that refuses to give bisantrene to patients assuming it does actually protect from cardiotoxicity.

Of course I understand why such conservative estimates have to be used, because as mentioned many times on this forum, the numbers genuinely look unbelievable.

This is truly a mind bogglingly large opportunity if executed to plan.

Expand

100% - sometimes we can really over complicate this stuff.

If it works, the conversations from the medical industry to patients will be

You can take dox - which will attack the cancer cells but there is a high chance of heart damage or you can take dox + bis - same cancer results but reduced risk of heart damage.

Especially from the same MST report... they note the NUMBER 1 concern by the Flemington straight from US clinicians is...
RAC Price at posting: $1.79 Sentiment: Buy Disclosure: Held
19 Upvote

0 Great analysis

Reply

Top Stories

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Aussie inflation seemingly hit a 3 year low. So why's the ASX200 red?

'We're looking': Nickel-rich Indonesia sounds graphite warning to Aus producers

The Altcoin Landscape (Part 1): Key alternative cryptocurrencies to watch

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

Bitcoin hits fresh record as instos pile into BTC ETFs – and Trump helps, too

Making money: How many microcaps should be in an investor's portfolio?

Week 44 Wrap: Relatively boring week ahead of US election; HotCopper's most watched; Oz inflation at 3.5%

MIN

Movers and Shakers: Zip Co, MinRes, Kuniko, more – The week's top ASX gainers

DXB

Dimerix links up with US NEPTUNE network to boost recruitment for FSGS study

There are more pages in this discussion • 422 more messages in this thread...

First 11590 Last

Add RAC (ASX) to my watchlist

(20min delay)
Last $1.47		Change 0.025(1.74%)		Mkt cap ! $249.7M

Open	High	Low	Value	Volume
$1.44	$1.48	$1.44	$25.63K	17.46K

Buyers (Bids)

No.	Vol.	Price($)
1	312	$1.47

Sellers (Offers)

Price($)	Vol.	No.
$1.48	354	1

View Market Depth

No.	Vol.	Price($)
1	312	1.465
2	2880	1.460
1	8653	1.450
1	548	1.440
1	2046	1.420

Price($)	Vol.	No.
1.475	354	1
1.480	11014	1
1.495	2500	1
1.500	4999	1
1.520	485	1

Last trade - 16.10pm 01/11/2024 (20 minute delay)

RAC (ASX) Chart

General Comments / Chat, page-11590

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Aussie inflation seemingly hit a 3 year low. So why's the ASX200 red?

'We're looking': Nickel-rich Indonesia sounds graphite warning to Aus producers

The Altcoin Landscape (Part 1): Key alternative cryptocurrencies to watch

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

Bitcoin hits fresh record as instos pile into BTC ETFs – and Trump helps, too

Making money: How many microcaps should be in an investor's portfolio?

Week 44 Wrap: Relatively boring week ahead of US election; HotCopper's most watched; Oz inflation at 3.5%

Movers and Shakers: Zip Co, MinRes, Kuniko, more – The week's top ASX gainers

Dimerix links up with US NEPTUNE network to boost recruitment for FSGS study

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

General Comments / Chat, page-11590

Top Stories

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Aussie inflation seemingly hit a 3 year low. So why's the ASX200 red?

'We're looking': Nickel-rich Indonesia sounds graphite warning to Aus producers

The Altcoin Landscape (Part 1): Key alternative cryptocurrencies to watch

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

Bitcoin hits fresh record as instos pile into BTC ETFs – and Trump helps, too

Making money: How many microcaps should be in an investor's portfolio?

Week 44 Wrap: Relatively boring week ahead of US election; HotCopper's most watched; Oz inflation at 3.5%

Movers and Shakers: Zip Co, MinRes, Kuniko, more – The week's top ASX gainers

Dimerix links up with US NEPTUNE network to boost recruitment for FSGS study

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News